The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).1
- An Epinephrine Nasal Spray (neffy) for Anaphylaxis
- Vonoprazan (Voquezna) for Nonerosive GERD
- A New RSV Vaccine (mResvia) for Adults ≥60 Years Old
- In Brief: New Warning for Fezolinetant (Veozah)
- Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old (online only)
- Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)
- Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only)
- In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)
- In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation (online only)
RELEASE
FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been approved by the FDA for self- or caregiver-administration. It is expected to be available for such use during the 2025-2026 influenza season.1 FluMist is only available through a healthcare provider this season. It will continue to be available for administration by a healthcare provider in the future.
DOSAGE AND ADMINISTRATION — FluMist is suppled in 0.2-mL single-use intranasal sprayer devices. The vaccine may contain residual amounts of ovalbumin (egg protein) and gentamicin sulfate. A single 0.2-mL dose (0.1 mL in each nostril) is recommended for most patients each season.1
Influenza vaccine for 2024-2025. Med Lett Drugs …